Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 5, 2025Neuro-OncologyOpen Access

P12.23.b Idh Inhibition at Relapse?

View Full Paper
Ask AI
Bookmark
Share

Authors

DKD KalapanidaSLStephanos LabropoulosGRGeorgios Rigakos

Discussion

Loading...

Member takes

Overview

Analysis reveals efficacy of ivosidenib in treating previously treated IDH mutant glioma patients, suggesting potential benefits beyond initial therapy.

Key Points

  • Ivosidenib shows satisfactory efficacy in previously treated patients with idh mutant gliomas and is well-tolerated.
  • In a sample of six patients, five remain stable on treatment, with one showing partial response.
  • Median treatment duration for patients is 133 days, indicating prolonged response with no adverse effects reported.
  • Further evaluation of idh inhibitors in relapsed settings may provide valuable insights for treatment options.

Cite This Study

Kalapanida et al. (2025) studied this question.

synapsesocial.com/papers/68e24e59d6d66a53c247300ahttps://doi.org/10.1093/neuonc/noaf193.402
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations2025 · 5 citations
  2. 2Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review2025 · 5 citations
  3. 3Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome2025
  4. 4Preserved IDH mutation and methylation class in vorasidenib non-responders: a report of two cases2025 · 1 citations
  5. 5Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial2025 · 2 citations